News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gemin X Biotechnologies Inc. Initiates a Phase 1 Trial with GMX1777 in Solid Tumors and Lymphomas


5/8/2007 12:37:32 PM

MONTREAL & BALLERUP, Denmark--(BUSINESS WIRE)--Gemin X announced today that it has initiated a Phase 1 clinical trial with GMX1777 in patients with refractory solid tumors and lymphomas. The compound, licensed worldwide from LEO Pharma, is a water-soluble, intravenously administered prodrug of the LEO Pharma compound CHS828.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES